Tests mosunetuzumab, a subcutaneous antibody, in untreated follicular lymphoma
Tests subcutaneous mosunetuzumab in adults newly diagnosed with low-burden follicular lymphoma.
Plain-language title generated from the registry record
Registry title: Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .
Key facts
- Where
- Haifa, Jerusalem, and Tel Aviv, IsraelSee the 4 sites
- Phase
- Phase 2
Where in Israel
- Rambam Health Care CampusHaifa, IsraelTaking people
- Shaare Zedek Medical CenterJerusalem, IsraelTaking people
- The Hadassah University Hospital-Ein KeremJerusalem, IsraelTaking people
- Tel Aviv Sourasky Medical Center (TASMC) - IchilovTel Aviv, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tel-Aviv Sourasky Medical Center
- Trial code
- NCT07191249
- Record updated
- 11 August 2026
- Original description
This is a multi-center, open-label, interventional clinical trial designed to evaluate the efficacy and safety of subcutaneous (SC) Mosunetuzumab as a first-line immunotherapy in patients with low tumor burden follicular lymphoma (LTB-FL), defined by the absence of GELF criteria.Read full original descriptionShow less
A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).
This is a multi-center, open-label, interventional clinical trial designed to evaluate the efficacy and safety of subcutaneous (SC) Mosunetuzumab as a first-line immunotherapy in patients with low tumor burden follicular lymphoma (LTB-FL), defined by the absence of GELF criteria.
Inclusion: at least 18 years old; Histologically confirmed classic FL (cFL) (according to WHO-HEAM4R classification); Low tumor burden by GELF criteria; No prior therapy except surgery or radiotherapy for disease that was previously localized; Ann Arbor Stage III or IV disease; Bi-dimensionally measurable FDG-avid disease defined by at least one single node or tumor lesion > 1.5 cm assessed by CT scan and/or clinical examination; Adequate hematologic function defined as follows without growth factors or blood product transfusion within 14 days of first dose of study drug administration:; Hemoglobin, without transfusion, 9 g/dL; ANC 1.0 109/L; Platelet count 75 109/L; Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2; Patient can understand and sign the Informed Consent Form (ICF), can communicate with the Investigator, can understand and comply with the requirements of the protocol.
Exclusion: Presence or history of CNS involvement by lymphoma; Contraindication to use Mosunetuzumabor known sensitivity or allergy; 1. An active viral infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) defined by detectable viral DNA in the blood by PCR. Patients with HIV are eligible provided an undetectable viral load and a CD4 count > 200 cell/mcl; 2. Any of the following laboratory abnormalities:; Total Bilirubin or GGT or AST or ALT > 3 X ULN; Creatinine Clearance calculated by Cockcroft and Gault Formula < 40 ml/min; 4. Prior history of malignancies other than Lymphoma (except for Basal Cell or Squamous Cell Carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 2 years; Pregnant or lactating females; 7. Female patients of childbearing potential who cannot or do not wish to use an effective method of contraception, during the study treatment and for 3 months thereafter.